We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Fifth Circuit’s Mifepristone Decision Would Engender Regulatory Chaos, Former FDA Officials Argue
Fifth Circuit’s Mifepristone Decision Would Engender Regulatory Chaos, Former FDA Officials Argue
Allowing courts to overturn science-driven drug approval decisions would open the door to a myriad of partisan legal challenges, exert a chilling effect on the business of drug development, and endanger patients, according to an amicus brief on the Fifth Circuit’s mifepristone restriction decision, filed by seven former FDA commissioners and acting commissioners.